Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of CS-7017 and Bexarotene

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven advanced malignancy with measurable disease except for acute leukemias~* Progression on, or intolerance of, or ineligibility for all standard therapies~* Biopsy accessible tumor deposits~* LVEF \>/= institutional normal~* No evidence of clinically significant fluid retention~* ECOG Performance status 0-2~* Subjects with no brain metastases or a history of previously treated brain metastases who have been treated with surgery or stereotactic radiosurgery at least 4 weeks prior to enrollment and have a baseline MRI that shows no evidence of intracranial disease and have not had treatment with steroids within one week of study enrollment.~* Adequate hepatic, bone marrow, and renal function~* Partial thromboplastin time must be \</= 1.5 x upper limit of normal range and INR \< 1.5. Subjects on anticoagulant will be permitted to enroll as long as the INR is in the acceptable therapeutic range~* Life expectancy \> 12 weeks~* Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.~* Subject is capable of understanding and complying with parameters of the protocol and able to sign and date the informed consent.~Exclusion Criteria:~* Prior CS-7017 treatment~* Treatment with thiazolidinediones (TZDs) within 4 weeks prior to start of study treatment~* Current need for concomitant use of other TZDs during the study~* Grade 2 or greater fasting hypertriglyceridemia~* Concurrent use of insulin~* Concurrent use of known CYP 3A4 inhibiting or activating medications~* CNS metastases which do not meet the criteria outlines in inclusion criteria~* Active severe infection or known chronic infection with HIV or hepatitis B virus~* Cardiovascular disease including unstable angina, therapy for life-threatening ventricular arrhythmia, or myocardial infarction, stroke or congestive heart failure within the last 6 months~* Life-threatening visceral disease or other severe concurrent disease~* Women who are pregnant or breastfeeding~* Anticipated survival under 3 months~* Clinically significant and uncontrolled major medical condition(s)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CS-7017 and Bexarotene (Type: EXPERIMENTAL): Combination of CS-7017 and Bexarotene

Based on this trial design, predict the completion outcome and termination type (if applicable).